מן הרשת 13.03.202216:05 ASCO GU 2022: Pembrolizumab As Post Nephrectomy Adjuvant Therapy for Patients With Renal Cell Carcinoma: Results From 30-Month Follow-Up of KEYNOTE-564 Uro Today
מן הרשת 13.03.202216:04 ASCO GU 2022: Predictors of Objective Response to First-Line Immuno-Oncology Combination Therapies in Metastatic Renal Cell Carcinoma: Results from the IMDC Uro Today
מן הרשת 13.03.202216:04 ASCO GU 2022: Safety and Differential Clinical Activity of Nivolumab plus Ipilimumab in Patients with Non-Clear Cell RCC Uro Today
מן הרשת 13.03.202216:02 ASCO GU 2022: Bladder-Sparing Trimodality Therapy Toxicity and Functional Outcomes in the Era of Novel Therapeutics Uro Today
מן הרשת 13.03.202216:00 Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy Uro Today
מן הרשת 13.03.202215:59 Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial Uro Today
מן הרשת 13.03.202215:59 Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer Uro Today
מן הרשת 13.03.202215:58 ASCO GU 2022: Role of Local Therapy for Prostate Cancer Variants The 2022 GU ASCO Annual meeting included a session on the management of rare variants in genitourinary cancers Uro Today
מן הרשת 13.03.202215:57 ASCO GU 2022: Optimizing Management of Localized Prostate Cancer Combined Modality Therapy in Localized Disease Uro Today
מן הרשת 13.03.202215:56 ASCO GU 2022: Active Surveillance for Patients with Intermediate-Risk Disease: Risk vs. Benefit 2022 GU ASCO Annual meeting included a session on the optimization management of localized prostate cancer, specifically looking at artificial intelligence (AI), active surveillance, and intervention Uro Today
מן הרשת 13.03.202215:55 ASCO GU 2022: Phase 1 study of PSCA-targeted CAR T cell therapy for mCRPC The 2022 GU ASCO Annual meeting included a prostate cancer session highlighting work from Dr. Tanya B. Dorff and colleagues presenting results of their phase 1 study assessing PSCA-targeted CAR T cell therapy for mCRPC Uro Today
מן הרשת 13.03.202215:54 ASCO GU 2022: Radiation Therapy in Localized Disease: Changing Horizons The 2022 GU ASCO Annual meeting included a session on the optimization management of localized prostate cancer, specifically looking at artificial intelligence (AI), active surveillance, and intervention Uro Today
מן הרשת 13.03.202215:53 ASCO GU 2022: ARASENS Trial Overall Survival With Darolutamide Versus Placebo in Combination With ADT and Docetaxel for mHSPC Uro Today
מן הרשת 16.01.202215:01 Patient Preference Between Cabazitaxel and Docetaxel for First-Line Chemotherapy in Metastatic Castration-Resistant Prostate Cancer European Urology
מן הרשת 16.01.202215:00 Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer Are second-generation antiandrogens (AAs) associated with increased risk of depression among older men diagnosed with prostate cancer? JAMA